72531-03-4Relevant articles and documents
Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques
Campos, Ludmila E.,Garibotto, Francisco M.,Angelina, Emilio,Kos, Jiri,Toma?i?, Tihomir,Zidar, Nace,Kikelj, Danijel,Gonec,Marvanova, Pavlina,Mokry, Petr,Jampilek,Alvarez, Sergio E.,Enriz, Ricardo D.
, (2019/08/12)
The identification of the V600E activating mutation in the protein kinase BRAF in around 50% of melanoma patients has driven the development of highly potent small inhibitors (BRAFi) of the mutated protein. To date, Dabrafenib and Vemurafenib, two specifi
Synthesis and in vitro antimycobacterial activity of novel n-arylpiperazines containing an ethane-1,2-diyl connecting chain
Gonec, Tomás,Malík, Ivan,Cs?llei, Jozef,Jampílek, Josef,Stolaríková, Jirina,Solovic, Ivan,Miku, Peter,Keltoová, Stanislava,Kollár, Peter,O'Mahony, Jim,Coffey, Aidan
, (2018/01/17)
Novel 1-(2-{3-/4-[(alkoxycarbonyl)amino]phenyl}-2-hydroxyethyl)-4-(2-fluorophenyl)-piperazin-1-ium chlorides (alkoxy = methoxy to butoxy; 8a-h) have been designed and synthesized through multistep reactions as a part of on-going research programme focused
